Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring Jan 21 | 2020New i-SENS BT BGM 510(k) Clearance; Integrity Non-invasive Glucose Meter CE Mark; Livongo Available to Horizon BCBS NJ; Jay Skyler Joins Oramed Advisory BoardPurchase Blast
$599
Posted in: GLP-1RA Jan 17 | 2020Thoughts on Ozempic CV Indication and Rybelsus Data-on-labelPurchase Blast
$599
Posted in: Dual/triple agonist, SGLT2i Jan 16 | 2020JPM 2020 Day 4: Lexicon and Hanmi; Generic Jardiance Tentative ApprovalPurchase Blast$599
Posted in: Insulin Delivery, Other Jan 15 | 2020JPM 2020 Day 3: No Diabetes Webcasts; Tandem Launches Control IQ; ADA Endorses Drug Affordability BillsPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal Jan 14 | 2020JPM 2020 Day 2: LLY, NVO, LVGO, SNY, PODD, ABT, and BDPurchase Blast$599
Posted in: Glucose Monitoring, Insulin Delivery Jan 13 | 2020JPM 2020 Day 1: DXCM, LVGO, Novo, Bigfoot Biomedical, Companion Medical, MDTPurchase Blast
$599
Posted in: Glucose Monitoring Jan 09 | 2020Livongo Partners with Higi; Dario Hires New President and Head of NAPurchase Blast
$599
Posted in: Glucagon Jan 07 | 2020Xeris RTU Glucagon Ph2 Results for Exercise-Induced HypoglycemiaPurchase Blast
$599
Posted in: Bolus Insulin, SGLT2i Jan 06 | 2020Farxiga DAPA-HF receives priority review; Fiasp pediatric approval in US; MannKind launching in BrazilPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, GLP-1RA, GLP-1RA + Basal, Glucagon, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jan 03 | 2020Thoughts on ADA 2020 Standards of CarePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin Jan 02 | 2020Novo Launches Insulin Savings ProgramPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Other Dec 19 | 2019Novo/UVA Partnership; Roche Decreases Eversense CGM Commitment; Lilly Insulin Pricing Open LetterPurchase Blast
$599
Posted in: Basal Insulin Dec 18 | 2019Rezolute Ultra-long-acting Basal Insulin (AB101) Ph1 Topline ResultsPurchase Blast
$599
Posted in: Insulin Delivery, SGLT2i Dec 17 | 2019Medtronic Acquires Klue; New Tandem SGLT2i+Closed-loop TrialPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, SGLT2i Dec 17 | 2019Tirzepatide CVOT vs. Trulicity; Lilly 2020 Guidance SummaryPurchase Blast
$599
Posted in: SGLT2i Dec 16 | 2019AZ Updates Farxiga Heart Failure Promotion on WebsitesPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Dec 16 | 2019Lilly/Dexcom Updated Partnership for CGMPurchase Blast
$599
Posted in: Insulin Delivery Dec 13 | 2019Tandem Control IQ Approved as first "iAlgorithm" DevicePurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
